Sign In
Buy IMRN
$1.09
-0.0200 (-1.80%)
At Close: Jul 31, 2026
Nano-Cap Drugmaker Surges 1,000% as Retail Enthusiasm Spreads
08:10pm, Tuesday, 09'th Jun 2020
(Bloomberg) -- Nano-cap Immuron Ltd. saw shares surge more than ten-fold on Tuesday afternoon as euphoria for retail traders took to the biopharmaceutical industry.The Australia-based company, which w
Immuron's stock blasts off nearly 10-fold after partner NMRC seeks pre-IND meeting with FDA
07:02pm, Tuesday, 09'th Jun 2020
The U.S.-listed shares of of Immuron Ltd. skyrocketed nearly 10-fold on massive volume in afternoon trading Tuesday, after the Australia-based biopharmaceutical company said its research partner, the
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pat
Immuron Board Relinquish Cash Payment of Fees
10:00am, Tuesday, 28'th Apr 2020
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today an
55 Stocks Moving In Monday's Mid-Day Session
04:43pm, Monday, 20'th Apr 2020
Gainers
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) shares climbed 93.6% to $12.41 after the company announced a collaboration agreement with the University of Edinburgh to...
Immuron North American Travelan Sales Up 95%, Global Sales Up 60%
10:00am, Monday, 20'th Apr 2020
Immuron achieved 60% YoY growth in worldwide product sales in Q3 FY20. YTD March 31, FY20 worldwide sales reached AU $2.67M, increasing 57% YoY. In Australia, Q3 FY20 gross sales grew by 35% YoY to
Reviewing IMMURON LTD/S (NASDAQ:IMRN) and Intec Pharma (NASDAQ:NTEC)
05:50am, Sunday, 12'th Apr 2020
IMMURON LTD/S (NASDAQ:IMRN) and Intec Pharma (NASDAQ:NTEC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends,
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) * Forty Seven Inc (NASDAQ: FTSV) * Masimo Corporat
Analyzing Intra-Cellular Therapies (NASDAQ:ITCI) and IMMURON LTD/S (NASDAQ:IMRN)
06:30am, Tuesday, 31'st Mar 2020
Intra-Cellular Therapies (NASDAQ:ITCI) and IMMURON LTD/S (NASDAQ:IMRN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength
The Daily Biotech Pulse: T2 Biosystems Licenses COVID-19 Test, Immuron CEO Steps Down
11:29am, Wednesday, 25'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 24) * BELLUS Health Inc (NASDAQ: BLU) * Global Cord
Resignation of CEO & Director and cost cutting amidst COVID-19
10:00am, Wednesday, 25'th Mar 2020
The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the Company. The keystone of this strategy will be the preservat
Is Immuron (ASX:IMC) In A Good Position To Invest In Growth?
12:17am, Thursday, 19'th Mar 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Immuron Provides Update on First Half of FY20 Results
12:00pm, Tuesday, 03'rd Mar 2020
Key Highlights: Strong continued growth of Travelan® sales reported in all marketsGlobal sales reached USD $1.1 million (AUD $1.68 million) for first half FY 2020 up 55% from.
Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak
12:30pm, Monday, 03'rd Feb 2020
Key Highlights: Wuhan coronavirus outbreak expanding to global health emergencyOutbreak while viral in nature highlights the role of global travel leading to respiratory and.
North American Travelan® sales up 98% in the first half of FY20
01:30pm, Tuesday, 28'th Jan 2020
Key Highlights: Strong continued growth of Travelan® sales reported in all marketsNorth American Travelan® sales up by 98% YoY in the first half of FY20Immuron achieved 55% YoY.
